Open AccessInvasive Pulmonary Aspergillosis in a Sickle Cell Patient Transplant Recipient: A Successful Treatment
Author(s) -
Katia Paciaroni,
Gioia De Angelis,
Cristiano Gallucci,
Cecilia Alfieri,
Michela Ribersani,
Andrea Roveda,
Antonella Isgrò,
Marco Marziali,
Ivan Pietro Aloi,
Alessandro Inserra,
Javid Gaziev,
Pietro Sodani,
G Lucarelli
Publication year - 2015
Publication title -
mediterranean journal of hematology and infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 31
ISSN - 2035-3006
DOI - 10.4084/mjhid.2015.006
Subject(s) - medicine , immunosuppression , aspergillosis , bone marrow transplant , bone marrow , hematopoietic stem cell transplantation , antifungal , intensive care medicine , transplantation , immunology , bone marrow transplantation , dermatology
Sickle Cell Anaemia (SCA) is the most common inherited blood disorder and is associated with severe morbidity and decreased survival. Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) is the only curative approach. Nevertheless the decision to perform a bone marrow transplant includes the risk of major complications and transplant-related mortality. Infections represent the leading cause of death in SCA patients undergoing HSCT. Invasive Pulmonary Aspergillosis (IPA) is a devastating opportunistic infection and remains a significant cause of morbidity and mortality in HSCT recipients. Data regarding IPA in the setting of SCA are lacking. In the present report, we describe a patient with SCA, who developed IPA after allogeneic bone marrow transplant. The fungal infection was treated by systemic antifungal therapy in addition to surgery, despite mild chronic graft versus host disease (GVHD) and continuing immunosuppressive therapy. This case shows that IPA occurring in bone marrow recipients with SCA can be successfully treated.